Different neuroinflammatory gene expression profiles in highly active and benign multiple sclerosis

2021 ◽  
pp. 577650
Author(s):  
Maria Ivanova ◽  
Anastasiya Voronkova ◽  
Vladimir Sukhorukov ◽  
Maria Zakharova
Keyword(s):  
Gene Expression ◽  
Multiple Sclerosis ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Highly Active ◽  
Benign Multiple Sclerosis

scholarly journals Identification of Monotonically Differentially Expressed Genes for IFN-β-Treated Multiple Sclerosis Patients

2019 ◽  
Vol 2019 ◽  
pp. 1-6 ◽  
Author(s):  
Suyan Tian ◽  
Lei Zhang
Keyword(s):  
Gene Expression ◽  
Multiple Sclerosis ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Biologically Relevant ◽  
Therapeutic Mechanism ◽  
The Central Nervous System ◽  
Multiple Sclerosis Patients ◽  
Term Response

Multiple sclerosis (MS) is a common neurological disability of the central nervous system. Immune-modulatory therapy with interferon-β (IFN-β) has been used as a first-line treatment to prevent relapses in MS patients. While the therapeutic mechanism of IFN-β has not been fully elucidated, the data of microarray experiments that collected longitudinal gene expression profiles to evaluate the long-term response of IFN-β treatment have been analyzed using statistical methods that were incapable of dealing with such data. In this study, the GeneRank method was applied to generate weighted gene expression values and the monotonically expressed genes (MEGs) for both IFN-β treatment responders and nonresponders were identified. The proposed procedure identified 13 MEGs for the responders and 2 MEGs for the nonresponders, most of which are biologically relevant to MS. Our work here provides some useful insight into the mechanism of IFN-β treatment for MS patients. A full understanding of the therapeutic mechanism will enable a more personalized treatment strategy possible.

Alterations in neuronal gene expression profiles in response to experimental demyelination and axonal transection

2010 ◽  
Vol 16 (3) ◽  
pp. 303-316 ◽  
Author(s):  
G. Lovas ◽  
JA Nielsen ◽  
KR Johnson ◽  
LD Hudson
Keyword(s):  
Gene Expression ◽  
Multiple Sclerosis ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Neurological Deficits ◽  
Activating Transcription Factor 3 ◽  
Post Intervention ◽  
Neuronal Gene ◽  
Activating Transcription Factor ◽  
Axonal Transection

The main pathological features of multiple sclerosis, demyelination and axonal transection, are considered to cause reversible and irreversible neurological deficits, respectively. This study aimed to separately analyze the effects of these pathological hallmarks on neuronal gene expression in experimental paradigms. The pontocerebellar pathway was targeted with either lysolecithin-induced chemical demyelination or a complete pathway transection (axonal transection) in rats. Transcriptional changes in the pontocerebellar neurons were investigated with microarrays at days 4, 10 and 37 post-intervention, which was confirmed by immunohistochemistry on protein level. A common as well as unique set of injury-response genes was identified. The increased expression of activating transcription factor 3 (Atf3) and thyrotropin-releasing hormone (Trh) in both injury paradigms was validated by immunohistochemistry. The expression of Atf3 in a patient with Marburg’s variant of multiple sclerosis was also detected, also confirming the activation of the Atf3 pathway in a human disease sample. It was concluded that this experimental approach may be useful for the identification of pathways that could be targeted for remyelinative or neuroprotective drug development.

Vitamin D-related gene expression profiles in immune cells of patients with relapsing remitting multiple sclerosis

2011 ◽  
Vol 235 (1-2) ◽  
pp. 91-97 ◽  
Author(s):  
Joost Smolders ◽  
Mariëlle Thewissen ◽  
Ruud Theunissen ◽  
Evelyn Peelen ◽  
Stephanie Knippenberg ◽  
...  
Keyword(s):  
Gene Expression ◽  
Multiple Sclerosis ◽  
Vitamin D ◽  
Immune Cells ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Related Gene ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

scholarly journals Gene expression profiles in Finnish twins with multiple sclerosis

2006 ◽  
Vol 7 (1) ◽  
Author(s):  
Silja Särkijärvi ◽  
Hanna Kuusisto ◽  
Raija Paalavuo ◽  
Mari Levula ◽  
Nina Airla ◽  
...  
Keyword(s):  
Gene Expression ◽  
Multiple Sclerosis ◽  
Expression Profiles ◽  
Gene Expression Profiles

scholarly journals Distinct gene expression profiles in leukocortical demyelinated white and grey matter areas of Multiple Sclerosis patients

2020 ◽  
Author(s):  
T.A. van Wageningen ◽  
E. Gerrits ◽  
A. Geleijnse ◽  
N. Brouwer ◽  
J.J.G. Geurts ◽  
...  
Keyword(s):  
Gene Expression ◽  
Multiple Sclerosis ◽  
Expression Profile ◽  
Grey Matter ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Distinct Gene ◽  
Distinct Gene Expression Profile ◽  
Multiple Sclerosis Patients ◽  
Insight Into

ABSTRACTDemyelination of the CNS is a prominent pathological hallmark of Multiple Sclerosis (MS) and affects both white (WM) and grey matter (GM). However, demyelinated WM and GM areas exhibit clear pathological differences, most notably the presence or absence of inflammation and activated glial cells in WM and GM, respectively. In order to gain more insight into the differential pathology of demyelinated WM and GM areas, we micro-dissected neighbouring WM and GM demyelinated areas as well as normal appearing matter from leukocortical lesions of human post-mortem material and used these samples for RNA-sequencing. Our data show that even neighbouring WM and GM demyelinated areas share only 10% overlap in gene expression, implying a distinct gene expression profile, which is extending to a specific glial cell related signature. We propose that, based on their distinct expression profile, pathological processes in neighbouring WM and GM are likely different which could have implications for the efficacy of current MS treatments.

Sign in / Sign up

Export Citation Format

Share Document